**Embeda® references**

Please note:

* Reference #16 is a subscription database and is therefore not included.

**References**

1. Embeda® [package insert]. New York (NY): Pfizer Inc.; 2014 Oct.
2. Statement of voluntary recall of Embeda® extended release capsules CII [press release on the internet]. New York (NY): King Pharmaceuticals Inc., a wholly owned subsidiary of Pfizer; 2011 Mar 16 [cited 2015 Nov 20]. Available at: http://www.pfizer.com/files/news/embeda\_recall\_031611.pdf
3. FDA approves labeling with abuse-deterrent features for third extended-release opioid analgesic [press release on the internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2014 Oct 17 [cited 2015 Nov 30]. Available at: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm419288.htm
4. Katz N, Sun S, Johnson F, Stauffer J. ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safety. The Journal of Pain. 2010;11(4):303-11.
5. Katz N, Hale M, Morris D, Stauffer J. Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis pain. Postgraduate Medicine. 2010;122(4):112-28.
6. Stauffer J, Setnik B, Sokolowska M, Romach M, Johnson F, Sellers E. Subjective effects and safety pf whole and tampered morphine sulfate and naltrexone hydrochloride (ALO-01) extended-release capsules versus morphine solution and placebo in experienced non-dependent opioid users. Clin Drug Investig. 2009;29(12):777-90.
7. Setnik B, Sommerville K, Goli V, Han L, Webster L. Assessment of pharmacodynamic effects following oral administration of crushed morphine sulfate and naltrexone hydrochloride extended-release capsules compared with crushed morphine sulfate controlled-release tables and placebo in nondependent recreational opioid users. Pain Medicine. 2013;14:1173-86.
8. Setnik B, Goli V, Levy-Cooperman N, Mills C, Shram M, Smith I. Assessing the subjective and physiological effects of intranasally administered crushed extended-release morphine formulations with and without a sequestered naltrexone core in recreational opioid users. Pain Res Manag. 2013;18(4):e55-62.
9. Webster LR, Johnson FK, Stauffer J, Setnik B, Ciric S. Impact of intravenous naltrexone on intravenous morphine-induced high, drug liking, and euphoric effects in experienced, nondependent male opioid users. Drugs R D. 2011;11(3):259-75.
10. Johnson FK, Stark JG, Bieberdorf FA, Stauffer J. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers. Clinical Therapeutics. 2010;32(6):1149-64.
11. Drugs@FDA [database on the Internet]. Rockville (MD): Food and Drug Administration (US), Center for Drug Evaluation and Research; 2015 [cited 2015 Dec 23]. Available from: <http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2014/022321Orig1s016ltr.pdf>
12. Bluelight [homepage on the Internet]. 2015 Dec 23 [cited 2015 Dec 23]. Available from: <http://www.bluelight.org>.
13. REMS@FDA [database on the Internet]. Rockville (MD): Food and Drug Administration (US), Center for Drug Evaluation and Research; 2015 [cited 2015 Dec 23]. Available from: <http://www.accessdata.fda.gov/scripts/cder/rems/index.cfm>
14. MS Contin® [package insert]. Stamford (CT): Purdue Pharma L.P.; 2014 Jun.
15. Kadian® [package insert]. Parsippany (NJ): Actavis Pharma Inc.; 2014 Aug.
16. U.S. Food and Drug Administration. FDA Drug Shortages: Current and Resolved Drug Shortages and Discontinuations Reported to the FDA [webpage on the internet]. Silver Spring (MD): U.S. Department of Health & Human Services; 2015 July [cited 2015 Nov 30]. Available at: http://www.accessdata.fda.gov/scripts/drugshortages/default.cfm
17. Avinza® [package insert]. Elizabeth (NJ): Actavis Elizabeth LLC; 2015 Feb.
18. U.S. Food and Drug Administration. Opioid Medications; Information on Opioid Medications [webpage on the internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2015 Nov 25 [cited 2015 Dec 3]. Available at: http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm337066.htm
19. Micromedex® Healthcare Series [database on the Internet]. Greenwood Village (CO): Thomson Healthcare; Updated periodically [cited 2015 Nov 23]. Available at: http://www.thomsonhc.com/.